Initial Dose-Escalation Results from the First-in-Human Ph 1 JEWEL-101 Trial Evaluating XB002 in Patients with Advanced Solid Tumors November 4, 2022
Updated Findings from the Ph 2 SUMMIT Basket Trial of Neratinib in EGFR Exon 18-Mutant NSCLC Presented November 4, 2022
FAILED TRIAL: Ph 2 AMEERA-3 trial of amcenestrant in ER+/HER2- advanced or metastatic breast cancer did not meet primary endpoint of improving PFS November 4, 2022
Preliminary Ph 1 Clinical Data from ARROS-1 Trial of NVL-520 for Patients with ROS1-Positive NSCLC reported November 4, 2022
Retrospective Analysis of Extended Treatment Benefit from Multiple Trials of Mirvetuximab Soravtansine in Ovarian Cancer presented November 2, 2022
Data from CheckMate -76K Shows that Opdivo Reduced the Risk of Recurrence or Death by 58% vs. Placebo in Patients with Completely Resected Stage IIB/C Melanoma October 26, 2022
Positive Topline Results Announced from Final PFS Analysis of BRUKINSA vs IMBRUVICA in Ph 3 ALPINE trial in CLL patients October 19, 2022
TRITON3 Ph 3 Trial Of Rubraca Achieves Primary Endpoint In Men With metastatic CRPC With BRCA Or ATM Mutations October 12, 2022
Ph 3 TALAPRO-2 study of TALZENNA® + XTANDI® in metastatic CRPC patients met primary endpoint of rPFS vs placebo plus XTANDI October 12, 2022
PERLA Ph 2 trial Of Jemperli (Dostarlimab) + Chemotherapy In Patients With mNSCLC met the primary endpoint of ORR October 12, 2022
Results Of IDMC Review Of 12 Week Safety Data From ENVASARC Ph 2 Pivotal Trial announced – Trial To Proceed As Planned October 12, 2022
New Long-Term Data from L-MIND Shows Durable Response to Monjuvi® (tafasitamab-cxix) for R/R DLBCL Patients October 5, 2022
CAR T-Cell Therapy Targeting GPRC5D Antigen Proves Effective in First Trial in Patients with Resistant Multiple Myeloma October 5, 2022
Gavo-cel Continues to Demonstrate Clinical Benefit in Solid Tumors with Additional RECIST Responses in Ovarian Cancer and Mesothelioma October 5, 2022
Long-Term Data from Omidubicel Ph 3 Trial Demonstrates OS and Sustainable Durable Outcomes for Patients with Blood Cancers October 5, 2022
Adjuvant Treatment with Opdivo Demonstrated Statistically Significant Improvement in RFS in Patients with Stage IIB/C Melanoma in the CheckMate-76K Trial September 28, 2022
Results from Ph 2 trial of zevorcabtagene autoleucel Ph 1b/2 study in RRMM patients announced September 28, 2022
Recommended Dose for Planned Registrational Study of NBTXR3 Plus Anti-PD-1 for Patients With mSCCHN Resistant to Prior Immunotherapy Established September 28, 2022
Lumakras® (Sotorasib) + Vectibix® (Panitumumab) Shows Confirmed 30% ORR In Patients With KRAS G12C-Mutated mCRC September 13, 2022
Imfinzi + chemo further improved OS benefit in advanced biliary tract cancer in the TOPAZ-1 Ph 3 trial, reducing the risk of death by 24% in additional follow-up September 13, 2022
Detailed Results from Ph 3 COSMIC-313 Pivotal Trial in Patients with 1L RCC announced September 13, 2022
Dose-Escalation Results from Ph 1 STELLAR-001 Trial of XL092 +/- atezolizumab in Patients with Advanced Solid Tumors announced September 13, 2022
